Combination Anti-HER2 Therapy with Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer (mBC) Previously Treated with Trastuzumab
Combination Anti-HER2 Therapy with Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer (mBC) Previously Treated with Trastuzumab
Slides from presentations at ASCO 2010 and transcribed comments from recent interviews with Kathy D Miller, MD (6/11/10) and Eric P Winer, MD (7/6/10)
Miller K et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for women with HER2-positive, locally advanced or metastatic breast cancer who were previously treated with trastuzumab. Proc ASCO 2010;Abstract 1012. Cortes J et al. Pertuzumab and trastuzumab: Exploratory biomarker correlations with clinical benefit in patients with metastatic HER2-positive breast cancer. Proc ASCO 2010;Abstract 1066. |
||||||||